CDMO Aptuit, which provides inhaled drug development and clinical supply manufacturing services, will be acquired by German CRO Evotec for $300 million, the two companies have announced.
Aptuit has about 750 employees at 3 sites in Italy, Switzerland, and the UK. In 2016, Aptuit acquired pre-clinical development specialist Kuecept, which also has extensive experience in respiratory drug development.
In 2012, Evotec partnered with IR Pharma for respiratory drug discovery services.
Aptuit CEO Jonathan Goldman said, “I am delighted that Aptuit’s unique value proposition of world-class scientists have combined with the Evotec team to create a best-in-class company. The operational management team and I look forward to continuing to offer customers an expanded set of solutions in discovery as part of the Evotec family as well as providing an end-to-end solution in candidate to IND (INDiGO) and Phase I to commercial integrated CMC needs. Our customers and staff can be reassured by the continuity of leadership and commitment by Evotec to invest in planned growth.”
Evotec Chief Operating Officer Mario Polywka commented, “Our strategy is to continuously increase the value of the company by expanding our leadership position in high-quality drug discovery and development solutions. The ability to provide a proven IND enabling platform and expertise will benefit our partners and customers in discovery as well as expedite progress of projects into Phase I and II. We look forward to welcoming our new colleagues to Evotec in what is an exciting time in the company’s strategic growth.”
Read the Aptuit and Evotec press release.
